# Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy

> **NCT04507035** · PHASE4 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Anlotinib hydrochloride capsules

## Key facts

- **NCT ID:** NCT04507035
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04507035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04507035, "Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04507035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*